Thomas Forst

Mannheim, BW, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 90 publications

Diabetes Mellitus and the Heart.

Diabetes Mellitus and the Heart.

Journal: Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
Published: May 29, 2026

Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial.

Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial.

Journal: Lancet (London, England)
Published: February 27, 2026

Type 1 Diabetes and Other Autoimmune Diseases-Epidemiology, Pathophysiology and Screening.

Type 1 Diabetes and Other Autoimmune Diseases-Epidemiology, Pathophysiology and Screening.

Journal: Endocrinology, diabetes & metabolism
Published: July 14, 2025

CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes.

CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes.

Journal: Cardiovascular diabetology
Published: February 18, 2025

Novel pharmacotherapies for weight loss: Understanding the role of incretins to enable weight loss and improved health outcomes.

Novel pharmacotherapies for weight loss: Understanding the role of incretins to enable weight loss and improved health outcomes.

Journal: Diabetes, obesity & metabolism
Published: November 26, 2024

Performance of a Novel Continuous Glucose Monitoring Device in People With Diabetes.

Performance of a Novel Continuous Glucose Monitoring Device in People With Diabetes.

Journal: Journal of diabetes science and technology
Published: August 19, 2024

A randomized phase I study of BI 1820237, a novel neuropeptide Y receptor type 2 agonist, alone or in combination with low-dose liraglutide in otherwise healthy men with overweight or obesity.

A randomized phase I study of BI 1820237, a novel neuropeptide Y receptor type 2 agonist, alone or in combination with low-dose liraglutide in otherwise healthy men with overweight or obesity.

Journal: Diabetes, obesity & metabolism
Published: June 05, 2024

The role of incretin receptor agonists in the treatment of obesity.

The role of incretin receptor agonists in the treatment of obesity.

Journal: Diabetes, obesity & metabolism
Published: May 03, 2024

CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes.

CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes.

Journal: Cardiovascular diabetology
Published: February 20, 2024

Diabetes Mellitus and the Heart.

Diabetes Mellitus and the Heart.

Journal: Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
Published: January 23, 2024

The Role of Ultra-Rapid-Acting Insulin Analogs in Diabetes: An Expert Consensus.

The Role of Ultra-Rapid-Acting Insulin Analogs in Diabetes: An Expert Consensus.

Journal: Journal of diabetes science and technology
Published: November 08, 2023

Non-alcoholic fatty liver disease in obese subjects as related to increasing insulin resistance and deteriorating glucose control: Three years of follow-up from a longitudinal survey.

Non-alcoholic fatty liver disease in obese subjects as related to increasing insulin resistance and deteriorating glucose control: Three years of follow-up from a longitudinal survey.

Journal: Journal of diabetes and metabolic disorders
Published: October 08, 2023
Showing 1-12 of 90

Last Updated: 09/26/2026